The role of epigenetics in tumor onset and progression has been extensively addressed.
Discoveries in the last decade completely changed our view on RNA. We now realize that its …

Currently, 10% of cancer chemotherapy is prescribed to patients by means of an oral
formulation, but, by 2013, this percentage is predicted to increase to 25%. Oral …

Chronic myeloid leukemia (CML) is a chronic disease resulting in myeloid cell expansion
through expression of the BCR-ABL1 fusion transcript. Tyrosine kinase inhibitors (TKI) have …

Type I and type II classes of interferons (IFNs) signal through the JAK/STAT1 pathway and
are known to be important in adaptive and innate immune responses and in protection …

Background Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …

For adult patients who present with chronic myeloid leukemia (CML) in chronic phase it is
now generally agreed that initial treatment should start with the tyrosine kinase inhibitor (TKI) …

Hepatocyte growth factor (HGF) and its receptor (c-Met) are associated with cancer cell
motility and invasiveness. p21-activated kinase 4 (PAK4), a potential therapeutic target, is …

Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic
myeloid leukemia (CML). However, a substantial number of patients develop resistance to …

Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) might be
crucial in comparing effectiveness of treatments as they could provide invaluable information …

The discovery that type I interferon (IFN-α/β) inhibited tumor cell growth was welcomed
initially with great excitement as it rapidly became a US Food and Drug Administration …